Results 101 to 110 of about 89,572 (287)

FAM107A loss facilitates TTK‐OPTN‐mediated mitophagy to drive docetaxel resistance in castration‐resistant prostate cancer

open access: yesInterdisciplinary Medicine, EarlyView.
In the progression of docetaxel resistance, downregulation of FAM107A releases its transcriptional repression of TTK, leading to TTK upregulation. TTK enhances the interaction and phosphorylation of OPTN. This activates mitophagy in tumor cells, facilitates clearance of damaged mitochondria, reduces intracellular reactive oxygen species accumulation ...
Yishan Zhang   +11 more
wiley   +1 more source

Data to establish the optimal standard regimen and predicting the response to docetaxel therapy

open access: yesData in Brief, 2015
This paper contains data to establish the optimal standard regimen and predicting the response to docetaxel therapy (Moawad, 2014) [1]. Docetaxel has been in use for over a decade without demonstrating data indicates a predictable response in the ...
Emad Y. Moawad
doaj   +1 more source

Docetaxel neuropathy: a distal axonopathy

open access: yes, 1999
Docetaxel has been implicated as a causative agent in peripheral neuropathy, but pathological changes in peripheral nerve have not been described. During docetaxel treatment a 54-year-old man developed a sensorimotor polyneuropathy when the overall ...
R. Fazio   +7 more
core   +1 more source

Unveiling the roles of extracellular vesicles in hematologic malignancies: Pathogenesis, diagnostic tools, and clinical translation

open access: yesInterdisciplinary Medicine, EarlyView.
Extracellular vesicles play pivotal roles in both healthy hematopoiesis and hematologic malignancies. They not only regulate hematopoietic stem cell fitness but also drive cancer progression and drug resistance. Their clinical potential spans from serving as non‐invasive biomarkers to acting as innovative therapeutic platforms and drug delivery ...
Fengyu Chen   +5 more
wiley   +1 more source

Docetaxel-Induced Systemic Sclerosis with Internal Organ Involvement Masquerading as Congestive Heart Failure

open access: yesCase Reports in Immunology, 2017
Systemic sclerosis, or scleroderma, is a complex medical disorder characterized by limited or diffuse skin thickening with frequent involvement of internal organs such as lungs, gastrointestinal tract, or kidneys.
Bumsoo Park   +4 more
doaj   +1 more source

Docetaxel-loaded PLGA and PLGA-PEG nanoparticles for intravenous application: pharmacokinetics and biodistribution profile

open access: yes, 2017
Pedram Rafiei, Azita Haddadi Division of Pharmacy, College of Pharmacy and Nutrition, University of Saskatchewan, Saskatoon, SK, Canada Abstract: Docetaxel is a highly potent anticancer agent being used in a wide spectrum of cancer types.
Rafiei P, Haddadi A
core  

Fat Mass and Obesity‐Associated Protein Contributes to Tumorigenesis and Drug Resistance of Diffuse Large B‐Cell Lymphoma by Suppressing N6‐Methyladenosine Methylation of Myc

open access: yesThe Kaohsiung Journal of Medical Sciences, EarlyView.
ABSTRACT Ibrutinib resistance remains a major obstacle in the treatment of diffuse large B‐cell lymphoma (DLBCL). Fat mass and obesity‐associated protein (FTO) has been implicated in drug resistance through its regulation of N6‐methyladenosine (m6A) modifications; however, whether FTO mediates ibrutinib resistance in DLBCL remains unclear.
Ting‐Ting Lu   +5 more
wiley   +1 more source

Hemorrhagic Cystitis in a Patient Receiving Docetaxel for Prostate Cancer

open access: yesClinical Medicine Insights: Oncology, 2010
A case is reported in which docetaxel was used to treat a patient with hormone refractory metastatic prostate cancer. The treatment was terminated at the third course of docetaxel following the development of hemorrhagic cystitis.
A.I. Ntekim, A. Ajekigbe
doaj   +1 more source

Patient management and docetaxel

open access: yes, 1997
Potent new drugs such as docetaxel (Taxotere®) will alter our perspective on advanced breast cancer, allowing significant disease responses and symptom palliation in many patients.
Val Aston
core   +1 more source

Risk Factors Influencing Efficacy and Prognosis Evaluation of Neoadjuvant Systemic Therapy in Triple‐Positive Breast Cancer

open access: yesThe Kaohsiung Journal of Medical Sciences, EarlyView.
ABSTRACT To identify the determinants of the response to neoadjuvant systemic therapy (NST) in triple‐positive breast cancer (TPBC), we retrospectively enrolled 520 patients with human epidermal growth factor receptor 2 (HER2)‐positive breast cancer who were treated at The First Affiliated Hospital of Chongqing Medical University between January 2015 ...
Lin‐Rui Miao   +7 more
wiley   +1 more source

Home - About - Disclaimer - Privacy